Results 91 to 100 of about 250,594 (213)

Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models. [PDF]

, 2019
Systemic delivery of antisense oligonucleotides (AO) for DMD exon skipping has proven effective for reframing DMD mRNA, rescuing dystrophin expression, and slowing disease progression in animal models.
Barthélémy, Florian, Douine, Emilie D, Hsu, Christopher, Marcantonio, Eugene E, Miceli, M Carrie, Nelson, Stanley F, Wang, Richard T   +6 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles. [PDF]

, 2019
Targeted delivery of lysosomal enzymes to the endocytic compartment of human cells represents a transformative technology for treating a large family of lysosomal storage diseases (LSDs).
Brown, Annie, Do, Mai Anh, Levy, Daniel, Lu, Biao, Marriott, Gerard   +4 more
core   +1 more source

Liver-Targeting of Interferon-Alpha with Tissue-Specific Domain Antibodies [PDF]

, 2013
PMCID: PMC3581439This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
A Trahtenherts, A Walker, Adam Walker, AM Wu, Armin Sepp, B Saunier, C. Andrew Boswell, CL Van Broekhoven, Clare Mudd, DJ Peng, DY Yang, E Dieperink, Edward Coulstock, ES Ward, F Pacifico, G Dusheiko, Gráinne Dunlevy, Jane Sosabowski, Jerome Burnet, JH Park, Julie Foster, KA Deal, Laura Goodall, LC Platanias, LJ Holt, LJ Holt, M Abe, M Loignon, M Spiess, Marie Davies, Milan Ovečka, MW Fried, MW Fried, P Kallinteri, R Duncan, R Gay, R Iorio, Rob Prince, T Eto, U Iyer, U Treichel, WM Pardridge, XQ Zhang, Y Zhang, YI Jeong, YY Seow   +45 more
core   +3 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. [PDF]

, 2016
Renal cell carcinoma (RCC) is increasing in incidence, and a complete cure remains elusive. While immune-checkpoint antibodies are promising, interferon-based immunotherapy has been disappointing.
Abu Aboud, Omran, Anderson, Katie, Berryhill, Grace, Chen, Ching-Hsien, Graef, Ashley, Hovey, Russell C, Kim, Jeffrey, Modiano, Jaime F, Sarver, Aaron L, Stewart, Benjamin, Trott, Josephine F, Uzal, Francisco, Weiss, Robert H, Wettersten, Hiromi   +13 more
core   +2 more sources

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas

EJNMMI Physics
Background A new, alternative option for patients with recurrent glioblastoma is targeted alpha therapy (TAT), in the form of a local administration of substance P (neurokinin type 1 receptor ligand, NK-1) labelled with 225Ac.
Monika Tulik, Radosław Kuliński, Zbisław Tabor, Beata Brzozowska, Piotr Łaba, Frank Bruchertseifer, Alfred Morgenstern, Leszek Królicki, Jolanta Kunikowska   +8 more
doaj   +1 more source

Essential gene pathways for glioblastoma stem cells: clinical implications for prevention of tumor recurrence. [PDF]

, 2011
Glioblastoma (World Health Organization/WHO grade IV) is the most common and most aggressive adult glial tumor. Patients with glioblastoma, despite being treated with gross total resection and post-operative radiation/chemotherapy, will almost always ...
Choe, Jinny, Liau, Linda M, Liu, Yue, Tso, Cho-Lea, Tso, Jonathan, Yamada, Kazunari, Ye, Fei   +6 more
core   +1 more source

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns, Jaclyn S. Long, Sergio Lilla, Kelly Hodge, Marcus J. G. W. Ladds, Colin Nixon, Paula Fernández‐Palanca, Sara Zanivan, Pilar Acedo, Stephen P. Pereira, Kevin M. Ryan   +10 more
wiley   +1 more source